Skip to main content

Table 2 Results of GLM model

From: Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes

 

Vildagliptin

Glibenclamide

Treatment effect

Time effect

Interaction

HBA1C (%)

 Baseline

7.7 (7.4–7.9)

7.7 (7.5–8.1)

p = 0.85

p < 0.001

p = 0.17

 4 months

6.8 (6.4–7.3)

6.8 (6.4–7.3)

 12 months

7.0 (6.5–7.3)

7.1 (6.5–7.5)

FPG (mg/dl)

 Baseline

155 ± 36

150 ± 30

p = 0.80

p < 0.001

p = 0.64

 4 months

130 ± 36

129 ± 28

 12 months

129 ± 28

129 ± 30

BMI (kg/m2)

 Baseline

29 (27–33)

29 (25–34)

p = 0.80

p = 0.67

p = 0.79

 4 months

29 (26–33)

28 (26–33)

 12 months

24 (26–33)

29 (26–34)

eGFR (ml/min/1.73 m2)

 Baseline

96.1 ± 11.8

96.0 ± 14.5

p = 0.24

p = 0.039

p = 0.55

 4 months

95.8 ± 10.5

92.3 ± 14.7

 12 months

95.8 ± 12.0

92.5 ± 12.9

EPC (n/106 events)

 Baseline

39.0 (24.0–58.2)

37.5 (25–59.8)

p = 0.025

p = 0.008

p = 0.58

 4 months

37.0 (27.0–65.0)

36.0 (23.0–54.2)

 12 months

45.0 (29.7–67)

32.0 (22.2–53.5)

Circulating markers

 SDF-1α (pg/ml)

  Baseline

2877 (2388–3713)

3134 (2763–4117)

p < 0.001

p = 0.38

p = 0.035

  4 months

2293 (1585–3187)

3100 (2572–3782)

  12 months

2064 (1540–2954)

3336 (2778–3863)

 BNP (pg/ml)

  Baseline

3 (1–9)

3 (2–7)

p = 0.41

p = 0.045

p = 0.71

  4 months

3 (1–8)

3 (1–5)

  12 months

5 (3–12)

6 (3–10)

 IL-6 (pg/ml)

  Baseline

4.7 (3.0–7.6)

6.1 (4.2–9.2)

p = 0.93

p = 0.77

p = 0.15

  4 months

5.8 (3.7–9.7)

5.4 (3.5–8.2)

  12 months

5.0 (2.7–9.9)

5.4 (3.7–6.7)

 CRP (mg/l)

  Baseline

4.0 (3.2–5.7)

3.8 (2.6–6.3)

p = 0.43

p = 0.51

p = 0.79

  4 months

4.0 (2.7–5.5)

3.2 (2.4–6.3)

  12 months

3.6 (2.3–6.1)

3.5 (2.9–3.9)

 TNFα (pg/ml)

  Baseline

1.4 (0.7–2.0)

1.6 (1.1–2.4)

p = 0.24

p = 0.25

p = 0.97

  4 months

1.1 (0.5–1.8)

1.7 (1.3–2.4)

  12 months

1.1 (0.4–1.8)

1.4 (0.8–2.2)

 GLP-1 total (pM)

  Baseline

84.0 (66.2–109.0)

86.7 (73.7–97.0)

p = 0.75

p = 0.83

p = 0.91

  4 months

  

  12 months

83.4 (68.8–107.0)

88.5 (75.5–114.6)

  1. Data are reported as mean ± standard deviation or median (IQR)
  2. Clinical variables, circulating markers and p values of GLM models (treatment, time and time × treatment effects)
  3. GLM model for primary (EPC) and secondary (SDF-1α) endpoint was performed with adjustment for baseline levels
  4. Statistically significant values (p < 0.05) are shown in italics